Introduction

Gitelman Syndrome is a rare disease that affects the kidneys and leads to the excessive loss of salt through the urine, resulting in symptoms such as dehydration and muscle weakness due to a lack of water in the body. This genetic condition often affects multiple members of a family, but symptoms may not present at birth; rather, they typically emerge during the patient’s teenage years. The condition is usually treated by replenishing the kidney’s salt supply with magnesium and potassium supplements, which can help reduce symptoms such as nausea, fatigue, and fainting (Blanchard et al., 2017). However, Gitelman syndrome may present with milder symptoms, which can delay diagnosis in teenagers, as patients may only experience symptoms such as cravings for salt or water, as well as frequent urination. 

Epidemiology

As the condition is very rare, affecting only about 25 people per million (Parmer et al., 2024), it is not commonly diagnosed, especially due to its similarity to other kidney dysfunctions, such as Bartter syndrome, which can lead to misdiagnosis in some cases. However, the number of affected individuals has primarily been recorded in Caucasians, so statistics may differ for people of other backgrounds. There are currently no known statistics comparing the prevalence of the condition between men and women. 

Pathophysiology

The distal convoluted tubule (DCT) in the kidneys is responsible for reabsorbing a certain percentage of salts, such as magnesium, calcium, and potassium, from urea that will be secreted from the body as waste products from the diet. These salts need to be reabsorbed within the kidneys, as they are charged and help maintain the balance of water concentration of urea, also known as electrolytes. If urea has a high percentage of water concentration, it usually indicates that there is a healthy or excess amount of water in the body, and so more needs to be secreted from the kidneys, which is controlled by the percentage of salts that are transported back into the DCT from urea. However, in patients with Gitelman syndrome, only a small percentage of salts are reabsorbed back into the DCT due to a mutation in the DCT cells, leading to excessive water release from the body through urea and causing dehydration (Schlingmann et al., 2022). 

Etiology

The disease is autosomal recessive, meaning that there is a 25% chance that a child may suffer from Gitelman syndrome if both parents are carriers of the mutated gene (Gitelman et al., 1966). The mutation in DCT cells that control salt reabsorption can arise from problems with salt transporters, which are associated with a mutation of the SLC12A3 gene (Vargas-Poussou et al., 2011), or from issues with the mitochondria in DCT cells, which can be caused by mutations of the MT-TI and MT-TF genes(Wilson et al., 2004). 

A SLC12A3 gene mutation in patients can lead to inefficient transportation of salts from urea into DCT cells, where they are reabsorbed into the blood again to regulate the concentration of water absorption and release from the body. This gene was the first to be found associated with Gitelman syndrome and is linked to the classic symptoms presented in early adolescence if a fault is found within the gene. If there is a mutation in the MT-TI or MT-TF genes, it usually involves a problem with the mitochondria within the DCT cells, resulting in insufficient energy for the transporters to work efficiently and transport a sufficient amount of salts back into the DCT and bloodstream from urea, leading to an excess of salts and water being excreted from the body and causing dehydration. MT-TI mutations typically produce symptoms mostly associated with Gitelman syndrome that present in adulthood, whereas MT-TF mutations can cause symptom presentation in both adulthood and childhood. 

There are other genes implicated in Gitelman syndrome that have been found in mutated forms in a smaller number of patients, such as the KCNJ10 gene. This mutation has been shown to cause insufficient transport of salts, such as magnesium and potassium, into the bloodstream. While this gene can cause similar symptoms to Gitelman syndrome, it may also present more serious symptoms, such as aphasia, deafness, and mental retardation. 

Due to the complex nature of how salts are transported into the bloodstream in the nephron through the distal convoluted tubule, there are a number of proteins that are essential for this process to occur smoothly. Therefore, there is a significant possibility that a specific protein involved in this process may be incorrectly formed due to a missense mutation, insertion, or deletion within the DNA during protein synthesis. This suggests that several genes could be responsible for the symptoms of Gitelman syndrome if there are issues during transcription or translation, indicating that more genes may be implicated in this disease that we have not yet discovered. 

FAQ’s

How does Gitelman syndrome differ from Bartter syndrome?

Gitelman syndrome is commonly discussed alongside Bartter syndrome in medical journals, as some aspects of these disorders exhibit very similar symptoms, leading to occasional overlap between them. The main difference between these two illnesses lies in the treatments that are most effective; Gitelman syndrome treatment addresses excessive water loss by using thiazide diuretics, whereas Barrter syndrome is treated using loop diuretics (Blanchard et al ., 2024).

Is the condition fatal?

Typically, the disease is treated by supplementing the lack of salts in the body through dietary intake. However, if this is not done or if the disease goes undiagnosed, it can lead to severe disruptions in daily life, such as chronic fatigue, abdominal pain, and nausea. However, these symptoms are extreme and the disease rarely causes life-threatening complications, and dietary changes are usually sufficient to manage it.

How is Gitelman syndrome diagnosed?

Usually, patients who complain of symptoms such as extreme thirst or salt cravings will be tested for certain markers in their blood and urine to determine what could be causing the problem. A high percentage of chloride and a low percentage of calcium in the urine typically suggests a tubular problem, such as Gitelman syndrome. 

Summary

Gitelman syndrome is a rare autosomal recessive condition that affects the kidney’s tubules, leading to inefficient salt transportation into the body. This causes symptoms such as dehydration, muscle weakness, fainting, salt cravings, and in extreme cases, nausea. Diagnosing this condition can be challenging, as symptoms usually present in early adolescence and may not seem too distressing, leading to a delay in diagnosis. Additionally, patients can sometimes be misdiagnosed with another tubular dysfunction, such as Barrter syndrome, due to the similarity of symptoms. However, these diseases primarily differ in the specific salts that are missing from the body. Supplementing salts in a patient's diet can help manage both diseases. 

Gitelman syndrome is caused by mutations in a set of genes responsible for transporting salts or providing the energy required for salt transport from urine into the bloodstream through the distal convoluted tubule in the kidneys. These mutations can disrupt the function of proteins involved in regulating the concentration of water and salts in urine, leading to an inefficient process. However, this is a rare condition, affecting less than 1% of the population, and symptoms can typically be managed with an accurate diagnosis.